Grzegorz Nowakowski, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Daiichi Sankyo, Inc.
    Date added: 
    09/29/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Karyopharm Therapeutics
    Date added: 
    09/29/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Kite Pharma, Inc.
    Date added: 
    09/29/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Karyopharm Therapeutics
    Date added: 
    09/29/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Bantam Pharmaceutical, LLC
    Date added: 
    09/29/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Zai Laboratory
    Date added: 
    09/29/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Kymera Therapeutics
    Date added: 
    09/29/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    TG Therapeutics, Inc
    Date added: 
    09/29/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Blueprint Medicines Corporation
    Date added: 
    09/29/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Constellation Pharmaceuticals
    Date added: 
    09/29/2023

Pages

Return to 2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes